The Latest Breaking News from FDA

Skin cancer is the most common cancer in the US and while sunscreen abounds in aisles, many aren’t applying it correctly

A growing number of Americans have reason to question the safety and efficacy of U.S. sunscreens.

The biotech industry's future is promising, driven by advanced technologies like AI and VR, the rising popularity of personalized treatments, and increased R&D spending. Let's analyze the investment prospects of biotech stocks Amgen (AMGN), United Therapeutics (UTHR), and Gilead Sciences (GILD) as potential breakthroughs emerge. Read more.

Humacyte is a pre-revenue biotech company that has delivered outsized gains to shareholders in 2024. But is the small-cap stock a good buy right now?

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling.

FDA advisers this week will scrutinize what could become the first approved psychedelic drug.

Smart rings are getting more popular by the year, but there are a few things keeping them from really breaking into the mainstream. Here's my wishlist for what these smart rings could really use.

The use of the drugs in treating low mood has sparked debate, not least about the necessity of a hallucinogenic experience. But a new discovery may provide an answer

Proposed legislation mandates folic acid in masa flour, sparking fears among traditional tortilla makers about costs and cultural impact.

Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.

MDMA could be reclassified as a prescription medicine and made available to specially certified doctors and therapists